Abstract
BackgroundPembrolizumab is approved in the United States for unresectable or metastatic microsatellite instability-high (MSI-H)/mismatch repair–deficient (dMMR) solid tumors that progress after treatment. As part of a post-marketing commitment, we conducted...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have